Plasma cotinine levels in cigarette smokers: Impact of mental health and other correlates

European Addiction Research

Volumn 20, Issue 4, 2014, Pages 183-191

  Bot, Mariska ^a   Vink, Jacqueline ^b   Milaneschi, Yuri ^a   Smit, Johannes H ^a   Kluft, Cornelis ^c   Neuteboom, Jacoline ^c   Penninx, Brenda ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c Good Biomarker Sciences   (Netherlands)

Author keywords

Anxiety; Cigarettes; Cotinine; Depression; Mental health; Smoking

Indexed keywords

COTININE;

ADULT; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DEPRESSION; DSM-IV; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MOOD DISORDER; NETHERLANDS; PRIORITY JOURNAL; SMOKING; TOBACCO CONSUMPTION; BLOOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGY; STATISTICAL MODEL; ASSESSMENT OF HUMANS; BECK ANXIETY INVENTORY; COHORT ANALYSIS; COMPARATIVE STUDY; INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY, SELF-REPORT VERSION; LONGITUDINAL STUDY;

ADULT; ANXIETY DISORDERS; COTININE; DEPRESSIVE DISORDER; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SMOKING;

EID: 84893198833     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000356809     Document Type: Article

References (50)

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al: Years lived with disability (YLDs) for 1160 sequelae of 2899 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163- 2196
2. Mykletun A, Overland S, Aaro LE, Liabo HM, Stewart R: Smoking in relation to anxiety and depression: Evidence from a large population survey: The HUNT study. Eur Psychiatry 2008; 23: 77-84
3. Kendler KS, Neale MC, Maclean CJ, Heath AC, Eaves LJ, Kessler RC: Smoking and major depression. A causal analysis. Arch Gen Psychiatry 1993; 50: 36-43
4. Breslau N, Peterson EL, Schultz LR, Chilcoat HD, Andreski P: Major depression and stages of smoking - A longitudinal investigation. Arch Gen Psychiatry 1998; 55: 161-166. (Pubitemid 28087602)
5. Johnson EO, Novak SP: Onset and persistence of daily smoking: The interplay of socioeconomic status, gender, and psychiatric disorders. Drug Alcohol Depend 2009; 104:S50- S57
6. Covey LS, Glassman AH, Stetner F: Cigarette smoking and major depression. J Addict Dis 1998; 17: 35-46. (Pubitemid 28156156)
7. Klungsoyr O, Nygard JF, Sorensen T, Sandanger I: Cigarette smoking and incidence of first depressive episode: An 11-year, populationbased follow-up study. Am J Epidemiol 2006; 163: 421-432
8. Moylan S, Jacka FN, Pasco JA, Berk M: Cigarette smoking, nicotine dependence and anxiety disorders: A systematic review of population- based, epidemiological studies. BMC Med 2012; 10: 123
9. Hukkanen J, Jacob P, Benowitz NL: Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79-115. (Pubitemid 40283970)
10. SRNT Subcommittee on Biochemical Verification: Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149-159
11. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang JT: Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 19999 and 2004. Am J Epidemiol 2009; 169: 236- 248
12. Blackford AL, Yang G, Hernandez-Avila M, Przewozniak K, Zatonski W, Figueiredo V, Avila-Tang E, Ma J, Benowitz NL, Samet JM: Cotinine concentration in smokers from different countries: Relationship with amount smoked and cigarette type. Cancer Epidemiol Biomarkers Prev 2006; 15: 1799-1804
13. Joseph AM, Hecht SS, Murphy SE, Carmella SG, Le CT, Zhang Y, Han SM, Hatsukami DK: Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev 2005; 14: 2963-2968. (Pubitemid 43071219)
14. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, Sharp DJ, Eriksen MP, Pirkle JL, Maurer KR: Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1998; 280: 135- 139
15. Campuzano JC, Hernandez-Avila M, Jaakkola MS, Ponce EL, Morales PK, Bautista P, Benowitz NL, Ceraso M, Blackford A, Samet JM: Determinants of salivary cotinine levels among current smokers in Mexico. Nicotine Tob Res 2004; 6: 997-1008. (Pubitemid 40124756)
16. Fidler JA, Jarvis MJ, Mindell J, West R: Nicotine intake in cigarette smokers in England: Distribution and demographic correlates. Cancer Epidemiol Biomarkers Prev 2008; 17: 3331-3336
17. Fu M, Fernandez E, Martinez-Sanchez JM, Pascual JA, Schiaffino A, Agudo A, Ariza C, Borras JM, Samet JM; DCOT Study investigators: Salivary cotinine concentrations in daily smokers in Barcelona, Spain: A crosssectional study. BMC Public Health 2009; 9: 320
18. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P: Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006; 79: 480-488
19. Perez-Stable EJ, Herrera B, Jacob P, Benowitz NL: Nicotine metabolism and intake in black and white smokers. JAMA 1998; 280: 152-156. (Pubitemid 28498387)
20. Kandel DB, Schaffran C, Griesler PC, Hu MC, Davies M, Benowitz N: Salivary cotinine concentration versus self-reported cigarette smoking: Three patterns of inconsistency in adolescence. Nicotine Tob Res 2006; 8: 525- 537
21. Perez-Stable EJ, Benowitz NL, Marin G: Is serum cotinine a better measure of cigarette smoking than self-report. Prev Med 1995; 24: 171-179
22. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJLM, Nolen WA, Zitman FG, Beekman ATF, Penninx BWJH: Comorbidity patterns of anxiety and depressive disorders in a large cohort study: The Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2011; 72: 341- 348
23. Penninx BWJH, Beekman ATF, Smit JH, Zitman FG, Nolen WA, Spinhoven P, Cuijpers P, De Jong PJ, Van Marwijk HWJ, Assendelft WJJ, Van der Meer K, Verhaak P, Wensing M, De Graaf R, Hoogendijk WJ, Ormel J, Van Dyck R: The Netherlands Study of Depression and Anxiety (NESDA): Rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121-140
24. Wittchen HU: Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI) - A critical review. J Psychiatr Res 1994; 28: 57-84
25. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 1996; 26: 477-486
26. Beck AT, Brown G, Epstein N, Steer RA: An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56: 893-897. (Pubitemid 19008360)
27. World Health Organization Collaboration Centre for Drug Statistics Methodology: Anatomical Therapeutic Chemical (ATC) Classification System. Oslo, World Health Organization, 2007
28. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-1395
29. Fu M, Martinez-Sanchez JM, Agudo A, Pascual JA, Borras JM, Samet JM, Fernandez E: Association between time to first cigarette after waking up and salivary cotinine concentration. Nicotine Tob Res 2011; 13: 168-172
30. Swan GE, Habina K, Means B, Jobe JB, Esposito JL: Saliva cotinine and recent smoking - evidence for a nonlinear relationship. Public Health Rep 1993; 108: 779-783. (Pubitemid 24015126)
31. Benowitz NL, Hukkanen J, Jacob P: Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009; 192: 29-60
32. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL: Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res 2005; 79: 323-335. (Pubitemid 41457273)
33. Strand JE, Nyback H: Tobacco use in schizophrenia: A study of cotinine concentrations in the saliva of patients and controls. Eur Psychiatry 2005; 20: 50-54
34. Williams JM, Gandhi KK, Lu SE, Kumar S, Shen J, Foulds J, Kipen H, Benowitz NL: Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob Res 2010; 12: 855-859
35. Malpass D, Higgs S: Acute psychomotor, subjective and physiological responses to smoking in depressed outpatient smokers and matched controls. Psychopharmacology 2007; 190: 363-372. (Pubitemid 46155645)
36. Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C: Individual differences in nicotine intake per cigarette. Cancer Epidemiol Biomarkers Prev 2003; 12: 468-471. (Pubitemid 36578488)
37. Fucito LM, Juliano LM: Depression moderates smoking behavior in response to a sad mood induction. Psychol Addict Behav 2009; 23: 546-551
38. Nakajima M, Yamamoto T, Nunoya KI, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y: Characterization of CYP2A6 involved in 3 ′ -hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 1010-1015
39. Gold AB, Lerman C: Pharmacogenetics of smoking cessation: Role of nicotine target and metabolism genes. Hum Genet 2012; 131: 857-876
40. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF: Ethnic variation in CYP2A66 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615-626
41. Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S: Association of CYP2A6 . 1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 2005; 5: 271- 275. (Pubitemid 41131719)
42. Rao YS, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF: Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747- 755
43. Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, Ueki R, Kawashima K, Hara H, Fujio Y, Azuma J: CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 2006; 6: 115-119
44. Zhu AZ, Renner C, Hatsukami DK, Swan G, Lerman CE, Benowitz NL, Tyndale RF: The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: The influence of genetics, race and sex. Cancer Epidemiol Biomarkers Prev 2013; 22: 708-718
45. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P: Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 2003; 5: 621-624. (Pubitemid 37304836)
46. West O, Hajek P, McRobbie H: Systematic review of the relationship between the 3-hydroxycotinine//cotinine ratio and cigarette dependence. Psychopharmacology 2011; 218: 313-322
47. Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R: Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther 2006; 80: 319-330. (Pubitemid 44479751)
48. Swan GE, Lessov-Schlaggar CN, Bergen AW, He YG, Tyndale RF, Benowitz NL: Genetic and environmental influences on the ratio of 3 ′ hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics 2009; 19: 388-398
49. Bandiera FC, Arheart KL, Caban-Martinez AJ, Fleming LE, McCollister K, Dietz NA, Leblanc WG, Davila EP, Lewis JE, Serdar B, Lee DJ: Secondhand smoke exposure and depressive symptoms. Psychosom Med 2010; 72: 68-72
50. Hamer M, Stamatakis E, Batty GD: Objectively assessed secondhand smoke exposure and mental health in adults: Cross-sectional and prospective evidence from the Scottish Health Survey. Arch Gen Psychiatry 2010; 67: 850-855.